Loading clinical trials...
Loading clinical trials...
A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Conditions
Interventions
IBI3009
Locations
10
Australia
Westmead Hospital
Westmead, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Austin Hospital
Heidelberg, Victoria, Australia
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Start Date
December 30, 2024
Primary Completion Date
August 30, 2027
Completion Date
August 30, 2027
Last Updated
February 11, 2025
NCT06305754
NCT06066138
NCT07485114
NCT07190248
NCT05692635
NCT07100080
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions